Comparing Tenaya Therapeutics (NASDAQ:TNYA) and Caribou Biosciences (NASDAQ:CRBU)

Caribou Biosciences (NASDAQ:CRBU) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation and risk.

Analyst Ratings

This is a summary of recent recommendations and price targets for Caribou Biosciences and Tenaya Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Caribou Biosciences	0	0	4	0	3.00
Tenaya Therapeutics	0	0	6	0	3.00

Caribou Biosciences presently has a consensus price target of $10.20, suggesting a potential upside of 466.67%. Tenaya Therapeutics has a consensus price target of $17.33, suggesting a potential upside of 937.92%. Given Tenaya Therapeutics’ higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Caribou Biosciences.

Profitability

This table compares Caribou Biosciences and Tenaya Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Caribou Biosciences	-1,290.81%	-45.46%	-38.07%
Tenaya Therapeutics	N/A	-86.17%	-71.14%

Institutional & Insider Ownership

77.5% of Caribou Biosciences shares are owned by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are owned by institutional investors. 9.5% of Caribou Biosciences shares are owned by insiders. Comparatively, 32.8% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Caribou Biosciences and Tenaya Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Caribou Biosciences	$11.48 million	14.20	-$102.07 million	($1.65)	-1.09
Tenaya Therapeutics	N/A	N/A	-$124.08 million	($1.44)	-1.16

Caribou Biosciences has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Caribou Biosciences has a beta of 2.27, suggesting that its stock price is 127% more volatile than the S&P 500. Comparatively, Tenaya Therapeutics has a beta of 2.72, suggesting that its stock price is 172% more volatile than the S&P 500.

Summary

Tenaya Therapeutics beats Caribou Biosciences on 7 of the 12 factors compared between the two stocks.

About Caribou Biosciences

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.